Krystal Biotech, Inc. (NASDAQ:KRYS) posted its quarterly earnings data on Monday. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.52), Bloomberg Earnings reports.

Shares of Krystal Biotech (KRYS) traded up $0.38 during mid-day trading on Tuesday, hitting $10.56. 46,600 shares of the stock traded hands, compared to its average volume of 32,297. Krystal Biotech has a twelve month low of $9.01 and a twelve month high of $11.98.

Separately, Ladenburg Thalmann Financial Services began coverage on shares of Krystal Biotech in a research report on Wednesday, October 18th. They issued a “buy” rating and a $23.00 price objective for the company.

In related news, COO Suma Krishnan purchased 100,000 shares of Krystal Biotech stock in a transaction dated Friday, September 22nd. The shares were acquired at an average price of $10.00 per share, with a total value of $1,000,000.00. Following the completion of the transaction, the chief operating officer now owns 1,935,249 shares of the company’s stock, valued at approximately $19,352,490. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Daniel Janney purchased 200,000 shares of Krystal Biotech stock in a transaction dated Friday, September 22nd. The shares were bought at an average cost of $10.00 per share, for a total transaction of $2,000,000.00. The disclosure for this purchase can be found here.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/krystal-biotech-inc-krys-issues-earnings-results/1702558.html.

Krystal Biotech Company Profile

Krystal Biotech, Inc gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases.

Receive News & Ratings for Krystal Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.